Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Arcturus Therapeutics Holdings, Inc.

http://www.arcturusrx.com

Latest From Arcturus Therapeutics Holdings, Inc.

Cipla Moves Into mRNA Arena With Stake In German Biotech Ethris

Cipla set to hold 10.35% in biotech Ethris, which is progressing inhaled mRNA-based therapies, among other key assets. The Indian firm expects its next wave of growth to come from areas like biosimilars and mRNA alongside lung leadership aspirations, putting the spotlight on the broader direction of the deal.

Commercial Deals

CSL Licenses Arcturus mRNA Technology, But COVID-19 Vaccine Remains Uncertain

The two companies signed a development and commercialization deal with a $200m upfront payment and milestones of up to $4.3bn.

Deals Platform Technologies

Finance Watch: Recent Upswing Turns Down, But Two Small IPOs Launch

Shuttle Pharmaceuticals and PaxMedica launch two small initial public offerings in the US as the market awaits a significant IPO. Also, Assertio closed a $70m follow-on offering, Codiak restructures and cuts jobs, and Vilya emerges with $50m in series A venture capital. 

Financing Restructuring

Arcturus Could Find Its COVID-19 Vaccine Limited To Smaller Markets

The company plans to seek an EUA in Vietnam for ARCT-154, but some analysts have questioned its prospects in major markets like the US.

See All

Company Information

UsernamePublicRestriction

Register